Alendronate decreases TRACP 5B activity in osteoarthritic bone

European Journal of Medical Research

Volumn 13, Issue 1, 2008, Pages 21-25

  Mehlhorn, Alexander T ^a,b   Rechl, H ^b   Gradinger, R ^b   Stemberger, A ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bisphosphonate; Bone; Osteoarthritis; Osteoclast; TRACP 5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MINERALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; FEMUR HEAD; FEVER; GASTROINTESTINAL DISEASE; HIP OSTEOARTHRITIS; HISTOCHEMISTRY; HUMAN; IMMUNOASSAY; MALE; OSTEOCLAST; RANDOMIZED CONTROLLED TRIAL;

ACID PHOSPHATASE; AGED; ALENDRONATE; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CELL COUNT; FEMALE; FEMUR HEAD; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOCLASTS;

EID: 38949163980     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ballanti P, Minisola S, Pacitti M T, Scarnecchia L, Rosso R, Mazzuoli G F, Bonucci E. Tartrate-resistant acid phosphate activity as osteoclastic marker: sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry. Osteoporos Int. 1997; 7(1): 39-43.
2. Benford H L, McGowan N W, Helfrich M H, Nuttall M E, Rogers M J. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001; 28 (5): 465-73.
3. Berenson J R, Lipton A. Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med 1999; 50: 237-48. Review.
4. Black D M, Reiss T F, Nevitt M C, Cauley J, Karpf D, Cummings S R. Design of the Fracture Intervention Trial. Osteoporos Tnt 1993; 3: S29-39.
5. Burr D B, Radin E L. Microfractures and microcracks in subchondral bone: are they relevant to osteoarthrosis? Rheum Dis Clin North Am 2003; 29: 675-85.
6. Burstone M S. Histochemical demonstration of acid phosphatase activity in osteoclasts. J Histochem Cytochem 1959; 7:39-41.
7. Cohen S B. An update on bisphosphonates. Curr Rheumatol Rep 2004; 6: 59-65.
8. Cole A A, Walters L M. Tartrate-resistant acid phosphatase in bone and cartilage following decalcification and cold-embedding in plastic. J Histochem Cytochem 1987; 35: 203-6.
9. Felsenberg D, Alenfeld F, Bock O, Hammermeister C, Gowan W. Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial. Maturitas 1998; 31: 35-44.
10. Fujita T, Fujii Y, Okada S F, Miyauchi A, Takagi Y. Analgesic effect of etidronate on degenerative joint disease. J Bone Miner Metab 2001; 19: 251-6.
11. Ghosh P, Cheras P A. Vascular mechanisms in osteoarthritis. Best Pract Res Clin Rheumatol 2001; 15: 693-709.
12. Halasy-Nagy J M, Rodan G A, Reszka A A. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 2001; 29: 553-9.
13. Halleen J M, Alatalo S L, Janckila A J, Woitge H W, Seibel M J, Vaananen H K. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 2001; 47: 597-600.
14. Halleen J M, Alatalo S L, Suominen H, Cheng S, Janckila A J, Vaananen H K. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15: 1337-45.
15. Hayami T, Pickarski M, Wesolowski G A, McLane J, Bone A, Destefano J, Rodan G A, Duong le T. The role of subchondral bone remodeling in osteoarthritis: Reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004; 50: 1193-206.
16. Imhof H, Breitenseher M, Kainberger F, Trattnig S. Importance of subchondral bone to articular cartilage in health and disease. Top Magn Reson Imaging 1999; 10: 180-92.
17. Janckila A J, Takahashi K, Sun S Z, Yam L T. Naphthol-ASBI phosphate as a preferred substrate for tartrate-resistant acid phosphatase isoform 5b. J Bone Miner Res 2001; 16: 788-93.
18. King L E, Grynpas M D, Tomlinson G, Vieth R. Pamidronate content and turnover in sternum, vertebral body, and iliac bones of dogs. Bone 1997; 20: 405-11.
19. Mankin H J, Dorfman H, Lippiello L, Zarins. A Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971; 53: 523-37.
20. Martinez M E, Del Campo M T, Plaza M A, Torrijos A, Gijon J. Pamidronate and biochemical markers of bone turnover. Scand J Clin Lab Invest 1997; 57: 581-6.
21. Muehleman C, Green J, Williams J M, Kuettner K E, Thonar E J, Sumner D R. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage 2002; 10: 226-33.
22. Myers S L, Brandt K D, Burr D B, O'Connor B L, Albrecht M. Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis. J Rheumatol 1999; 26: 2645-53.
23. Pedrazzoni M, Alfano F S, Gatti C, Fantuzzi M, Girasole G, Campanini C, Basini G, Passeri M. Acute effects of bisphosphonates on new and traditional markers of bone resorption. Calcif Tissue Int 1995; 57: 25-9.
24. Radin E L, Rose R M. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop 1986; 34-40.
25. Reimann I, Christensen S B. A histochemical study of alkaline and acid phosphatase activity in subchondral bone from osteoarthrotic human hips. Clin Orthop 1979; 85-91.
26. Rogers M J, Frith J C, Luckman S P, Coxon F P, Benford H L, Monkkonen J, Auriola S, Chilton K M, Russell R G. Molecular mechanisms of action of bisphosphonates. Bone 1999; 24: 73S-79S.
27. Scarnecchia L, Minisola S, Pacitti M T, Carnevale V, Romagnoli E, Rosso R, Mazzuoli G F. Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Invest 1991; 51: 517-24.
28. Spector T D. Bisphosphonates: potential therapeutic agents for disease modification in osteoarthritis. Aging Clin Exp Res 2003; 15: 413-8.